{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:12:55Z","timestamp":1788412375898,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100022416","name":"Center for Drug Evaluation and Research","doi-asserted-by":"publisher","award":["75F40120C0044"],"award-info":[{"award-number":["75F40120C0044"]}],"id":[{"id":"10.13039\/100022416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01AG068365"],"award-info":[{"award-number":["K01AG068365"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40264-024-01443-3","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T16:01:32Z","timestamp":1715875292000},"page":"909-919","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000\u20132020"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6684-2337","authenticated-orcid":false,"given":"Mufaddal","family":"Mahesri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameet","family":"Sarpatwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista F.","family":"Huybrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Lii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Been","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita A.","family":"Toyserkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"LaCivita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther H.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald J.","family":"Dal Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsiaryna","family":"Bykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"1443_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"1443_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94.","journal-title":"Blood Cancer J"},{"key":"1443_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1443_CR4","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.mayocp.2012.06.014","volume":"87","author":"TM Therneau","year":"2012","unstructured":"Therneau TM, Kyle RA, Melton LJ III, et al. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc. 2012;87:1071\u20139.","journal-title":"Mayo Clin Proc"},{"key":"1443_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1476-5381.1960.tb01217.x","volume":"15","author":"GF Somers","year":"1960","unstructured":"Somers GF. Pharmacological properties of thalidomide (a-phthalimido glutarimide), a new sedative. Br J Pharmacol Chemother. 1960;15:111\u20136.","journal-title":"Br J Pharmacol Chemother"},{"key":"1443_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/jmg.29.10.716","volume":"29","author":"RW Smithells","year":"1992","unstructured":"Smithells RW, Newman CG. Recognition of thalidomide defects. J Med Genet. 1992;29:716\u201323.","journal-title":"J Med Genet"},{"key":"1443_CR7","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1056\/NEJMp1210007","volume":"367","author":"JA Greene","year":"2012","unstructured":"Greene JA, Podolsky SH. Reform, regulation, and pharmaceuticals\u2014the Kefauver-Harris Amendments at 50. N Engl J Med. 2012;367:1481\u20133.","journal-title":"N Engl J Med"},{"key":"1443_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2165\/00002018-200629040-00003","volume":"29","author":"K Uhl","year":"2006","unstructured":"Uhl K, Cox E, Rogan R, et al. Thalidomide use in the US: experience with pregnancy testing in the S.T.E.P.S. programme. Drug Saf. 2006;29:321\u20139.","journal-title":"Drug Saf"},{"key":"1443_CR9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2165\/00002018-200831090-00003","volume":"31","author":"CP Castaneda","year":"2008","unstructured":"Castaneda CP, Zeldis JB, Freeman J, et al. RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide. Drug Saf. 2008;31:743\u201352.","journal-title":"Drug Saf"},{"issue":"12","key":"1443_CR10","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1056\/NEJMp1803910","volume":"379","author":"J Avorn","year":"2018","unstructured":"Avorn J, Kesselheim A, Sarpatwari A. The FDA Amendments Act of 2007\u2014assessing its effects a decade later. N Engl J Med. 2018;379(12):1097\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"1443_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40264-016-0501-2","volume":"40","author":"NA Brandenburg","year":"2017","unstructured":"Brandenburg NA, Bwire R, Freeman J, Houn F, Sheehan P, Zeldis JB. Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for lenalidomide and thalidomide: patient comprehension and knowledge retention. Drug Saf. 2017;40(4):333\u201341.","journal-title":"Drug Saf"},{"issue":"1","key":"1443_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1517\/14740338.2011.527331","volume":"10","author":"R Bwire","year":"2011","unstructured":"Bwire R, Freeman J, Houn F. Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective. Expert Opin Drug Saf. 2011;10(1):3\u20138.","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"1443_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40264-021-01070-2","volume":"44","author":"A Sarpatwari","year":"2021","unstructured":"Sarpatwari A, Mitra-Majumdar M, Bykov K, et al. A multi-modal approach to evaluate the impact of risk evaluation and mitigation strategy (REMS) programs. Drug Saf. 2021;44(7):743\u201351.","journal-title":"Drug Saf"},{"issue":"4","key":"1443_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","volume":"58","author":"S Schneeweiss","year":"2005","unstructured":"Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323\u201337.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"1443_CR15","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","volume":"64","author":"JJ Gagne","year":"2011","unstructured":"Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749\u201359.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"1443_CR16","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MLR.0000000000000824","volume":"55","author":"JW Sun","year":"2017","unstructured":"Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046\u201351.","journal-title":"Med Care"},{"issue":"9","key":"1443_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.38","volume":"3","author":"AA Chanan-Khan","year":"2013","unstructured":"Chanan-Khan AA, Swaika A, Paulus A, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013;3(9): e143.","journal-title":"Blood Cancer J"},{"issue":"10","key":"1443_CR18","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1182\/bloodadvances.2020001508","volume":"4","author":"R Alonso","year":"2020","unstructured":"Alonso R, Cedena MT, Wong S, Shah N, R\u00edos-Tamayo R, Moraleda JM, et al. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Adv. 2020;4(10):2163\u201371.","journal-title":"Blood Adv"},{"issue":"9","key":"1443_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41408-022-00719-0","volume":"12","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV, Kumar S, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 2022;12(9):129.","journal-title":"Blood Cancer J"},{"key":"1443_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.10.018","volume":"70","author":"J Luo","year":"2017","unstructured":"Luo J, Gagne JJ, Landon J, Avorn J, Kesselheim AS. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study. Eur J Cancer. 2017;70:22\u201333.","journal-title":"Eur J Cancer"},{"issue":"11","key":"1443_CR21","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360.","journal-title":"N Engl J Med"},{"issue":"1","key":"1443_CR22","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1038\/s41467-023-41223-8","volume":"14","author":"JH Huber","year":"2023","unstructured":"Huber JH, Mengmeng J, Shih YH, Wang M, Colditz G, Chang SH. Disentangling age, gender, and racial\/ethnic disparities in multiple myeloma burden: a modeling study. Nat Commun. 2023;14(1):5768.","journal-title":"Nat Commun"},{"issue":"1","key":"1443_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44386","volume":"5","author":"A Sarpatwari","year":"2022","unstructured":"Sarpatwari A, Brown BL, McGraw SA, Dejene SZ, Abdurrob A, Santiago Ortiz AJ, Kesselheim AS. Patient and caregiver experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use. JAMA Netw Open. 2022;5(1): e2144386.","journal-title":"JAMA Netw Open"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01443-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T14:23:59Z","timestamp":1723645439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01443-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1443"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01443-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"28 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected. Co-author's family name has been corrected as \u2018Dal Pan\u2019","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by the Center for Drug Evaluation and Research at the US FDA (Contract number 75F40120C0044). Ameet Sarpatwari and Aaron S. Kesselheim\u2019s work was also supported by grant funding from Arnold Ventures. Katsiaryna Bykov\u2019s effort was also supported by the National Institutes of Health (K01AG068365).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding Information"}},{"value":"Ameet Sarpatwari reports having served as an expert witness on REMS-related litigation concerning mifepristone. Katsiaryna Bykov reports consulting fees from Alosa Health for unrelated work. Mufaddal Mahesri, Krista F. Huybrechts, Joyce Lii, Su Been Lee, Gita A. Toyserkani, Cynthia LaCivita, Esther H. Zhou, Gerald J. Dal Pan, and Aaron S. Kesselheim have no conflicts of interest to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}},{"value":"The study was conducted using de-identified data and approved by the Mass General Brigham Institutional Review Board (IRB # 2020P002183).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval Statement"}},{"value":"Data supporting the findings of the study are available from the Centers of Medicare & Medicaid Services (CMS), Optum\u2019s de-identified Clinformatics\u00ae Data Mart Database, and Merative Marketscan. Restrictions apply to the availability of these data, which were used under license for this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Programming codes are available from the corresponding author upon request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability Statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate Statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish Statement"}},{"value":"MM, AS, KFH, GAT, CL, EHZ, GJDP, ASK, and KB contributed to the conception and design of the study. All authors analyzed the data. MM, AS, and KB wrote the first draft of the manuscript. All authors critically revised the manuscript and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}